Business: Late-stage biotech developing therapies for rare cholestatic liver diseases. Phreesia - New York, 7.8 million shares, priced $15-$17, ...
News
- Initial public offerings scheduled to debut next week
- Setbacks for Trump's drive to lower prescription drug costs
... forced to pay out of pocket for the medicines they need," Jim Greenwood, head of the Biotechnology Innovation Organization, said in a statement.
- Pebble Labs to expand biosciences business in New Mexico
LOS ALAMOS, N.M. (AP) — A company started by a former scientist at Los Alamos National Laboratory plans to expand over the next decade, ...
- All About People
... in Milwaukee, Wis., with a Bachelor of Science, Biomedical Sciences ... basic military training at Joint Base San Antonio-Lackland in San Antonio.
- US stocks drop on lower odds for steep Fed rate cut
PROMISING THERAPY: Sangamo Therapeutics surged 9.5% after a test of a therapy that the biotech company is working on to combat hemophilia ...